NHS England approves Lojuxta funding for HoFH

Will Lojuxta change the way Homozygous Familial Hypercholesterolaemia patients are treated?

EVENITY ™ Biologics License Application resubmitted for osteoporosis

Amgen and UCB have announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™ (romosozumab),...

Prime Minister & Trump urged to discuss sexual healthcare by RCOG & FSRH

Theresa May is urged to discuss abortion and contraception during talks with Trump

The Wasdell Group launches new serialisation service

The Wasdell Group, an outsourcing partner to companies within the pharmaceutical, medical device and clinical trials industries, has launched its serialisation service ahead of...

Abbott’s MitraClip® gets FDA approval to treat leaky heart valves

Abbott have received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device...

AbbVie’s FDA application for venetoclax in acute myeloid leukemia

Will AbbVie's new drug reshape how leukaemia is treated?

Children’s cancer drug dinutuximab beta recommended by NICE

Cancer drug for children of 12 months+ with high-risk neuroblastoma

Change for NHS as new Health Secretary appointed

The NHS faces more change as Matt Hancock takes over as Secretary of State for Health and Social Care, replacing Jeremy Hunt who has...

Seattle Genetics & Astellas complete enrolment for urothelial cancer trial

Seattle Genetics and Astellas Pharma have announced completion of enrolment for the enfortumab vedotin EV-201 pivotal phase 2 clinical trial cohort of patients with...

Mylan adds to CNS portfolio with Exelon ® Patch launch

Have Mylan made progress on Alzheimer's and Parkinson's disease treatment?

Latest articles

NHS trusts face worryingly high levels of senior vacancies

Why is high turnover among board-level roles make a negative impact on the performance of NHS trusts?

Triumph for Roche’s flu drug in phase III study

Roche has announced that the phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications...

Leading Alzheimer’s Disease scientist joins NeuroCog Trials

Dr. Kathleen Anne Welsh-Bohmer, a specialist in Alzheimer’s Disease research, has joined the scientific leadership team at NeuroCog Trials (NCT) as the Vice President...